Cue Biopharma (NASDAQ:CUE) CEO Sells $305,446.85 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 11,087 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $27.55, for a total value of $305,446.85. Following the completion of the transaction, the chief executive officer directly owned 694,908 shares of the company’s stock, valued at approximately $19,144,715.40. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The shares were sold at an average price of $28.62, for a total value of $522,543.96.
• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00.

Cue Biopharma Trading Down 10.5%

Shares of Cue Biopharma stock traded down $1.96 during trading hours on Friday, reaching $16.71. The stock had a trading volume of 106,462 shares, compared to its average volume of 475,957. The firm has a market capitalization of $121.31 million, a PE ratio of -0.62 and a beta of 2.62. Cue Biopharma, Inc. has a twelve month low of $4.97 and a twelve month high of $45.50. The stock’s 50 day moving average is $27.36 and its 200 day moving average is $70.48.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings data on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. The business had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. As a group, sell-side analysts predict that Cue Biopharma, Inc. will post -21.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CUE has been the topic of several research analyst reports. B. Riley Financial began coverage on Cue Biopharma in a report on Friday, September 18th. They issued a “buy” rating and a $83.00 price objective on the stock. Weiss Ratings cut Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 27th. Zacks Research raised Cue Biopharma to a “hold” rating in a report on Monday, September 21st. Finally, Wall Street Zen downgraded Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cue Biopharma presently has an average rating of “Hold” and an average target price of $83.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Cue Biopharma in the 2nd quarter valued at about $1,824,000. ADAR1 Capital Management LLC acquired a new position in shares of Cue Biopharma during the second quarter worth $1,742,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Cue Biopharma during the second quarter worth $722,000. Persistent Asset Partners Ltd acquired a new position in shares of Cue Biopharma during the second quarter worth $389,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of Cue Biopharma during the second quarter worth $83,000. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.